Introduction
7-Bromo-8-methyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one is a fused nitrogen- and oxygen-containing heterocyclic compound with potential value in pharmaceutical intermediate synthesis.
Its structure integrates a pyridine ring and an oxazinone ring into a fused bicyclic system. The molecule also contains a bromine substituent and a methyl group, providing additional opportunities for structural modification.
The combination of a fused heterocyclic core and an aromatic bromine substituent makes this compound a useful building block for medicinal chemistry and pharmaceutical research.
Product Information
- · Product Name: 7-Bromo-8-methyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one
- · CAS Number: 2169906-54-9
- · Molecular Formula: C₈H₇BrN₂O₂
- · Molecular Weight: 243.06 g/mol
- · Chemical Class: Brominated fused pyrido-oxazinone
- · Core Structure: Pyrido[2,3-b][1,4]oxazinone
The molecular formula and molecular weight are reported in chemical reference databases.
Understanding the Fused Heterocyclic Structure
The compound contains a fused pyridine-oxazinone ring system.
This structural arrangement provides a relatively rigid molecular framework, which can be useful in pharmaceutical molecule design.
Three structural features are particularly important.
1. Fused Pyridine-Oxazinone Core
The fused bicyclic framework contains both nitrogen and oxygen atoms.
These heteroatoms contribute to the compound’s electronic properties and provide a defined arrangement of hydrogen-bond donor and acceptor sites.
The rigid fused-ring architecture can also help maintain a consistent molecular geometry during subsequent synthesis.
2. Bromine Substituent
The bromine atom at the 7-position is an important functionalization site.
It can potentially participate in palladium-catalyzed cross-coupling reactions, allowing the introduction of additional aromatic or heteroaromatic groups.
This makes the compound relevant to convergent synthesis strategies in which a preformed heterocyclic core is connected to another molecular fragment.
3. Methyl Substituent
The methyl group at the 8-position distinguishes this compound from the corresponding non-methylated analog.
This substitution changes the electronic and steric environment of the fused heterocycle and must be maintained when the target molecular structure requires this specific substitution pattern.
Synthetic Relationships and Related Heterocycles
The pyrido[2,3-b][1,4]oxazinone family includes several related compounds with different oxidation states and substitution patterns.
For example, CAS 105544-36-3 is the non-methylated 7-bromo pyrido-oxazinone analog, while CAS 2169906-55-0 is the corresponding 7-bromo-8-methyl dihydro-pyrido-oxazine.
These compounds should not be treated as interchangeable. The presence or absence of the 8-methyl group and the oxidation state of the oxazine ring change the molecular formula and chemical behavior.
The 8-methylated oxazinone structure may be considered for further reduction or functionalization depending on the intended synthetic route.
However, the specific connection between CAS 2169906-54-9 and GNE-6893 is not established by the publicly available GNE-6893 process-development paper. Buyers should verify the target API mapping against the actual route before treating it as a confirmed GNE-6893 intermediate.
Potential Value in Pharmaceutical Intermediate Research
Fused heterocycles are important structural components in many pharmaceutical research programs.
The pyrido-oxazinone scaffold offers several features that can be useful in molecular design:
- · A rigid bicyclic framework
- · Multiple heteroatoms
- · A defined substitution pattern
- · A bromine-based functionalization site
- · Opportunities for downstream structural diversification
For process chemists, the bromine substituent may provide a route to substituted fused heterocycles through suitable coupling chemistry.
The oxazinone functionality may also be modified under appropriate reaction conditions to access related oxazine structures.
Quality Control for Pharmaceutical Procurement
Because this compound contains both a fused heterocyclic system and a reactive aromatic halogen, quality evaluation should address structural identity and related impurities.
|
Quality Attribute |
Buyer Consideration |
| Chemical identity | Confirm the fused-ring structure and substitution positions |
| Assay | Establish main-component content by an agreed method |
| Related substances | Monitor structurally related heterocycles |
| Brominated impurities | Evaluate unreacted precursors and related brominated compounds |
| Water content | Assess moisture levels where relevant |
| Residual solvents | Review process-related solvent residues |
| Batch consistency | Compare analytical profiles across production batches |
NMR and mass spectrometry can help confirm the molecular structure, while HPLC or an appropriate chromatographic method can be used to evaluate purity and related substances.
For downstream coupling applications, it is especially important to establish a consistent impurity profile.
Supplier Evaluation for Advanced Heterocyclic Intermediates
When purchasing CAS 2169906-54-9, buyers should consider the supplier’s ability to provide reliable quality information and consistent batches.
Recommended procurement checks include:
1. Batch-specific COA availability.
2. HPLC purity and related-substance data.
3. NMR or other structural identification support.
4. Sample availability for downstream process evaluation.
5. Storage and packaging recommendations.
6. Customized specifications where required.
A supplier capable of discussing both analytical quality and downstream synthetic requirements can provide additional value during process development.
Shanghai Lizhuo Pharmaceutical Technology
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. provides pharmaceutical intermediate R&D, custom synthesis, and production-related services.
Its stated technical resources include a 1,000 m² R&D laboratory, pilot production workshops, and reaction equipment supporting a range of chemical process conditions.
For customers evaluating fused heterocyclic intermediates such as CAS 2169906-54-9, potential cooperation areas include product specification confirmation, sample evaluation, custom synthesis, and batch-quality coordination.
More information is available through the official company profile.
Conclusion
7-Bromo-8-methyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one is a brominated fused heterocyclic building block with a defined pyridine-oxazinone framework.
Its bromine substituent provides an opportunity for further molecular functionalization, while the fused ring and methyl substitution establish a specific structural pattern.
For pharmaceutical procurement, reliable structural identification, controlled related substances, and consistent batch quality are essential to supporting downstream synthesis.
Post time: Nov-13-2026
